<DOC>
	<DOCNO>NCT01178697</DOCNO>
	<brief_summary>This randomize clinical trial conduct evaluate effect three intravitreal injection bevasizumab versus two intravitreal injection triamcinolone acute central retinal vein occlusion . The outcome visual acuity central macular thickness . The follow-up time 6 month .</brief_summary>
	<brief_title>Intravitreal Bevasizumab Versus Intravitreal Triamcinolone Central Retinal Vein Occlusion ( CRVO )</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Recent onset ( le 3 month ) central retinal vein occlusion Any previous intervention</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>